FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/11/2024
Voltar para busca
Dado oficial do USPTO
MYRIAMED
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MYRIAMED
ST13
US500000079350987Classe
1, 5, 9, 42
Pedido
79350987
Registro
7376414
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
23/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9, 42
Data de depósito
07/04/2022
Data de registro
07/05/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/05/2024
Última transação
07/05/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
28
Localização do titular
DE
Examinador
ELLINGER FATHY, JESSICA
Unidade examinadora
M10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
myriamed GmbH
Representantes
Michael A. Whittaker Acuity Law Group
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industry and sciencein particular reagents for cultivation of cells and tissue; cells for research or for scientific purposescellsin particular genetically modified cellshuman cells and cells derived from induced pluripotent stem cellsin particular cardiomyocytes derived from human induced pluripotent stem cellsskeletal cells derived from human induced pluripotent stem cellsstroma cells derived from human induced pluripotent stem cellsneuronal cells derived from human induced pluripotent stem cells; biological tissuesother than for medical or veterinary purposestissues in particular engineered tissuesin particular tissue comprising cells derived from induced pluripotent stem cells and macroscale muscle tissuein particular human heart muscle constructed from cardiomyocytes derived from human induced pluripotent stem cellshuman skeletal muscle constructed from skeletal cells derived from human induced pluripotent stem cellshuman fibrotic tissue constructed from stroma cells derived from human induced pluripotent stem cellsconnective tissue constructed from connective tissue cells derived from human induced pluripotent stem cellsbrain tissue derived from human induced pluripotent stem cellsneuronal organoids; biological preparation for use in cell cultures other than for medical or veterinary use; biological tissue culturesother than for medical or veterinary purposes; biological tissue culturesother than for medical or veterinary purposesdisease models based on engineered tissue or engineered cells
Classe 5
Pharmaceutical and veterinary preparationsin particular cells and tissues for treatment of cardiac diseasesdegenerative muscular diseasesfibrotic diseasesneurodegenerative diseasesconnective tissue diseases or disorders with impaired scaring and wound healing; pharmaceutical preparations for the renewal and regeneration of organs; pharmaceutical preparations for use in cellular therapy; biological tissue derived from stem cells for medical purposes; tissue-regenerative pharmaceutical preparations
Classe 9
Scientific research and laboratory apparatus for drug screening or potency assays; cell culture apparatus for laboratory usein particular cell culture plates and tissue culture plates for the generation and/or cultivation of engineered tissue
Classe 42
Scientific and industrial research in particular in the biochemicaldiagnostic or pharmaceutical fields; biochemical or pharmaceutical laboratory servicesin particular in the field of cultivation of cells and tissues; drug discovery servicesin particular drug discovery services based on tissue engineered organ platforms; scientific and technological services and research in the field of regenerative medicine; cell culture services for scientific and research purposesfor others
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
31/10/2024
FIMP
FINAL DISPOSITION PROCESSED
30/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/08/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/05/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/05/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
25/03/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/03/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/03/2024
GPNX
NOTIFICATION PROCESSED BY IB
26/02/2024
PUBO
PUBLISHED FOR OPPOSITION
20/02/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/02/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/01/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/09/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/09/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/09/2023
RFNT
REFUSAL PROCESSED BY IB
25/04/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
31/03/2023
RFRR
REFUSAL PROCESSED BY MPU
31/03/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/02/2023
CNRT
NON-FINAL ACTION WRITTEN
11/02/2023
DOCK
ASSIGNED TO EXAMINER
25/01/2023
MAFR
APPLICATION FILING RECEIPT MAILED
04/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
30/09/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
29/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MYRIAMED ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.